Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo?
In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line. Last month, the FDA rejected the lead NASH drug contender, obeticholic acid, due to concerns that its risks outweigh its benefits. This action leaves Madrigal Pharmaceuticals’